JAMA Oncology

JAMA Oncology JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed publications.

In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab...
01/25/2026

In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%.

https://ja.ma/4k1WdzU

Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal co...
01/25/2026

Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal conventional adenomas versus those with the lowest intake; no significant association was seen for serrated lesions. https://ja.ma/4jYTZBn

Phase 2 trial finds lorlatinib yielded a 73% objective response rate and median progression-free survival of 53.6 months...
01/25/2026

Phase 2 trial finds lorlatinib yielded a 73% objective response rate and median progression-free survival of 53.6 months in TKI-naive advanced ROS1-positive NSCLC. https://ja.ma/4bXdQyC

💬 Editorial: Metastatic recurrence nearly triples mortality risk in among young adults and increases death risk in sar...
01/24/2026

💬 Editorial: Metastatic recurrence nearly triples mortality risk in among young adults and increases death risk in sarcoma and colorectal cancer—highlighting the need for earlier detection and novel treatments. https://ja.ma/4pUWVA8

Among adolescents and young adults with , 9.5% of patients with earlier-stage cancer experienced metastatic recurrence ...
01/24/2026

Among adolescents and young adults with , 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).

Metastatic recurrence was more frequent in patients diagnosed at higher stages and, except for testicular and thyroid cancers, survival after metastatic recurrence was worse than for those who had metastatic disease at diagnosis.

https://ja.ma/4jWdmLp

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with ...
01/23/2026

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids.

https://ja.ma/4qDr1JP

Adjuvant immunotherapy is increasingly integrated into cancer care to reduce recurrence and improve survival. However, i...
01/22/2026

Adjuvant immunotherapy is increasingly integrated into cancer care to reduce recurrence and improve survival. However, its high cost raises critical concerns regarding affordability and economic value across diverse health system contexts.

This Review outlines health gains and economic value, and identifies where future research, pricing reform, or prioritization are needed to support evidence-informed policymaking and sustainable use of immunotherapy in cancer treatment pathways.

https://ja.ma/3LGGIkc

Incorporating clinical comorbidity and MRI-based factors, the IMPACT tool accurately predicted disease progression risk,...
01/22/2026

Incorporating clinical comorbidity and MRI-based factors, the IMPACT tool accurately predicted disease progression risk, enabling clinicians to stratify patients into early intervention, serial monitoring, or discharge from outpatient care.

Individuals with high-risk meningiomas had a progression rate of approximately 50%, medium-risk 24%, and low-risk under 4%, supporting tailored clinical management pathways.

https://ja.ma/49Na34x

Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT wi...
01/21/2026

Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group. https://ja.ma/3NvzPmn

Among men with undergoing hormone therapy, inhibitor use was associated with lower risk of treatment failure and del...
01/19/2026

Among men with undergoing hormone therapy, inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit.

https://ja.ma/4qvhJ2t

The 2025 federal restrictions are projected to cause over 1 million missed exams and over 150 excess deaths within...
01/19/2026

The 2025 federal restrictions are projected to cause over 1 million missed exams and over 150 excess deaths within 2 years, with substantial impact on younger and vulnerable adults.

https://ja.ma/4bAM8Ys

CHIP was associated with increased heart failure and ischemic cardiovascular disease risk after therapy in patients wi...
01/19/2026

CHIP was associated with increased heart failure and ischemic cardiovascular disease risk after therapy in patients with solid tumors, especially among those with higher exposure.

https://ja.ma/45kROSy

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category